| 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0212 | 0.1616 | -86.88 | 0.1327 | | 每股净资产（元） | 5.11 | 4.66 | 9.66 | 4.46 | | 每股公积金(元) | 0.29 | 0.29 | 0 | 0.29 | | 每股未分配利润(元) | 2.63 | 2.22 | 18.47 | 2.09 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 5.04 | 4.62 | 9.09 | 4.59 | | 净利润(亿元) | 0.05 | 0.36 | -86.11 | 0.3 | | 净资产收益率(%) | 0.42 | 3.51 | -88.03 | 3.04 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 三、分红送配方案情况 本次公司不分配不转赠。 前十大流通股东累计持有： 12055.95 ...

上天天基金APP搜索【777】领 98 元券包 ，优选基金10元起投！限量发放！先到先得！ 作为资本市场的重要"稳定器"和"压舱石"，社保基金凭借审慎稳健的投资运营管理，已经成为A股市场 长期投资、理性投资的典范。 根据A股上市公司2025年一季报披露，截至4月28日记者发稿，一季度末已有324家公司前十大流通股股 东名单中出现社保基金的身影，社保基金最新投资路线图逐次揭晓。东方财富Choice数据显示，上述 324家公司累计获社保基金重仓持股54.97亿股，对应持股市值为853.85亿元。 社保基金新进持有100家上市公司 今年一季度，社保基金对云铝股份、华鲁恒升、常熟银行、万华化学、赤峰黄金、广汇能源、西部超 导、新奥股份、宇通客车、宝钢股份、长城汽车等15家公司的重仓持股市值超过10亿元。其中，社保基 金持有云铝股份1.45亿股，对应持仓市值为25.13亿元；持有华鲁恒升1.06亿股，对应持仓市值23.42亿 元；持有常熟银行2.54亿股，对应持仓市值为17.7亿元；持有万华化学2121万股，对应持仓市值为14.26 亿元；持有赤峰黄金6145.75万股，对应持仓市值为14.07亿元；持有广汇能源2.1 ...

Performance Overview - The company reported a decline in performance for Q1 2025, with total revenue of 8.437 billion yuan, a year-on-year decrease of 1.87% [1] - The net profit attributable to shareholders was 101 million yuan, down 5.7% year-on-year, while the net profit excluding non-recurring items was 98.678 million yuan, a decrease of 4.54% [1] Profitability Analysis - The company's gross margin stood at 6.0%, a decrease of 6.35 percentage points year-on-year, and the net profit margin was 1.41%, down 5.55 percentage points [2] Expense Control - Total operating expenses (selling, administrative, and financial expenses) amounted to 301 million yuan, with an expense-to-revenue ratio of 3.57%, which is a year-on-year reduction of 12.12% [3] Asset and Cash Flow Situation - The company's cash and cash equivalents were 1.114 billion yuan, a decline of 29.75% compared to 1.586 billion yuan in the same period last year [4] - Operating cash flow per share was -5.11 yuan, a decrease of 39.28% year-on-year, indicating significant challenges in cash flow management [4] Accounts Receivable and Debt Situation - As of the end of the reporting period, accounts receivable amounted to 8.402 billion yuan, an increase of 5.44% year-on-year, with interest-bearing debt at 4.294 billion yuan, down 2.95% [5] - The ratio of accounts receivable to profit was as high as 1598.78%, necessitating close monitoring of collection [5] Business Model and Capital Return - Over its 29 years since listing, the company has raised a total of 2.272 billion yuan and distributed dividends totaling 332 million yuan, resulting in a dividend-to-financing ratio of 0.15 [6] - The company's performance heavily relies on equity financing and marketing efforts, raising questions about the sustainability of this business model [6] Summary - Overall, the company's performance in Q1 2025 was unsatisfactory, particularly in terms of profitability, cash flow management, and accounts receivable, which pose significant risks [7]

近日，中证投服中心提名上峰水泥独立董事候选人，并向投资者公开征集表决权。这是A股第二个由投 资者保护机构提名上市公司独董候选人的案例，标志着独董提名正从"少数人推荐"向"投资者广泛参 与"的多元化生态迈进。 过去，独董提名权长期掌控在董事会以及大股东手中。中小投资者的声音和诉求在决策过程中容易被忽 略，在一定程度上限制了独董监督制衡作用的发挥。 独董提名渠道的拓宽，一方面打破了原有的提名局限，让更多具备专业能力和独立性的人士有机会进入 独董队伍，为上市公司治理注入新鲜血液。另一方面，通过公开征集股东委托，提名权得以延伸至中小 投资者群体，显著提升了中小投资者在公司治理中的参与度与话语权。 以往，中小投资者因持股分散等原因，难以发挥实质性作用。如今，中证投服中心将分散的中小股东投 票权汇聚起来，形成强大的"表决权合力"。随着越来越多的投资者尤其是中小投资者，参与到独董提名 中来，独董生态将更加多元、健康。当独董能够切实发挥独立、高效的监督作用时，上市公司的治理水 平将得到全方位提升，进而促进资本市场的健康稳定发展。 （文章来源：证券时报网） 随着独董制度改革的不断深化，"独董不独"等曾经困扰市场的难题正在逐步化 ...

Financial Performance - The company's basic earnings per share decreased to 0.1000 yuan in 2024 from 0.2400 yuan in 2023, representing a decline of 58.33% [1] - Net profit fell to 0.35 billion yuan in 2024, down 57.32% from 0.82 billion yuan in 2023 [1] - Operating revenue decreased to 37.41 billion yuan in 2024, an 8.89% drop compared to 41.06 billion yuan in 2023 [1] - The return on equity (ROE) dropped to 1.76% in 2024 from 4.19% in 2023, a decline of 58% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 46.81 million shares, accounting for 16.61% of the circulating shares, with an increase of 3.61 million shares compared to the previous period [1] - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 31.23 million shares, representing 11.07% of the total share capital [2] - New entrants among the top shareholders include Wang Chenghua with 2.84 million shares and Zhao Shuiju with 2.14 million shares [2] Dividend Distribution - The company announced a dividend distribution of 0.6 yuan per share (including tax) [3]

证券研究报告·公司点评报告·医药商业 一心堂（002727） 2024 年年报及 2025 年一季报点评：利润短 期承压，省外扩张成效显著 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 17,380 | 18,000 | 20,189 | 22,307 | 24,490 | | 同比（%） | (0.29) | 3.57 | 12.16 | 10.49 | 9.79 | | 归母净利润（百万元） | 549.44 | 114.14 | 642.45 | 717.17 | 797.64 | | 同比（%） | (45.60) | (79.23) | 462.87 | 11.63 | 11.22 | | EPS-最新摊薄（元/股） | 0.94 | 0.19 | 1.10 | 1.22 | 1.36 | | P/E（现价&最新摊薄） | 15.24 | 73.37 | 13.03 | 11.68 | 10.50 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 26.497 billion yuan in 2024, representing an 8.01% year-on-year increase, while the net profit attributable to shareholders was 914.76 million yuan, a decrease of 21.58% year-on-year. The first quarter of 2025 saw a revenue of 6.956 billion yuan, up 3.02% year-on-year, and a net profit of 460 million yuan, an increase of 15.45% year-on-year, exceeding expectations [8] - The company has optimized its store structure, which is expected to drive profit growth. As of the first quarter of 2025, the company had 16,622 stores across 21 provinces, with a net increase of 69 stores in the quarter [8] - The report highlights a decline in various expense ratios in the first quarter of 2025, indicating effective cost control measures [8] Financial Performance Summary - Total revenue projections for the company are as follows: 2023A: 24.531 billion yuan, 2024A: 26.497 billion yuan, 2025E: 29.587 billion yuan, 2026E: 32.673 billion yuan, and 2027E: 35.861 billion yuan [1] - The net profit attributable to shareholders is projected to be 1.1665 billion yuan in 2023A, 914.76 million yuan in 2024A, 1.08432 billion yuan in 2025E, 1.25219 billion yuan in 2026E, and 1.44462 billion yuan in 2027E [1] - The earnings per share (EPS) are forecasted to be 1.02 yuan in 2023A, 0.80 yuan in 2024A, 0.95 yuan in 2025E, 1.10 yuan in 2026E, and 1.27 yuan in 2027E [1] Store Expansion and Structure Optimization - The company has been actively optimizing its store layout, with a total of 16,622 stores as of the first quarter of 2025, including 6,239 franchise stores. The company closed 174 stores during the quarter, which is part of its strategy to enhance profitability [8] - The report indicates that the company plans to continue its store expansion, albeit at a slower pace, with a total of 2,479 new stores added in 2024 [8] Profitability Metrics - The gross profit margin for 2024 was reported at 34.33%, a decrease of 1.57 percentage points year-on-year, while the net profit margin was 3.70%, down 1.32 percentage points year-on-year [8] - The company expects to achieve a net profit of 1.084 billion yuan in 2025, reflecting an 18.54% growth compared to the previous year [1]

Core Insights - Shanghai Pharmaceuticals reported a revenue of 70.763 billion yuan for Q1 2025, representing a year-on-year growth of 0.87% [1] - The company achieved a net profit attributable to shareholders of 1.333 billion yuan during the same period [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 5.885 billion yuan [1] - The pharmaceutical commercial segment accounted for sales of 64.878 billion yuan [1] Business Growth Areas - The import agency business achieved sales of 8.6 billion yuan, reflecting a year-on-year increase of 9.0% [1] - The innovative drug business reported sales of 12.5 billion yuan, with a significant growth of 23.2% [1] - The CSO (Contract Sales Organization) business saw a revenue increase of 9.89% [2] - The health equipment segment generated sales of 10.9 billion yuan, marking a growth of 6.9% [2] Strategic Initiatives - Shanghai Pharmaceuticals launched the "Lingang New Area Medical Device Import and Export Service Center" to facilitate the import of urgently needed drugs and rare disease medications [1] - The company established strategic partnerships with firms like Ansell and Kangfang Biotech to enhance the commercialization of new drugs [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company's brand operation business shows steady growth, with increased sales expenses impacting profitability [4][5] - In 2024, the company achieved a revenue of 8.09 billion yuan, a year-on-year decrease of 2.0%, while the adjusted revenue was 8.57 billion yuan [5] - The net profit attributable to shareholders for 2024 was 690 million yuan, down 2.9% year-on-year [5] - For Q1 2025, the company reported a revenue of 1.84 billion yuan, a slight decrease of 0.4% year-on-year, and a net profit of 90 million yuan, down 54.4% year-on-year [5] Business Segmentation Summary - **Brand Operation**: Revenue reached 5.56 billion yuan, up 9.2% year-on-year; adjusted revenue was 6.04 billion yuan [8] - Key products include: - Diquan: 2.1 billion yuan, up 10.7% - Hailu: 740 million yuan, up 14.9% - Baiyang Pharmaceutical: 950 million yuan, with core product revenue of 630 million yuan, up 16.6% [8] - **Wholesale Distribution**: Revenue decreased to 2.14 billion yuan, down 23% year-on-year as the company focuses on core brand operations [8] - **Retail Business**: Revenue remained stable at 370 million yuan, up 3.7% year-on-year [8] Financial Performance and Forecast - The gross margin for 2024 was 35.5%, an increase of 2.2 percentage points year-on-year, with brand operation gross margin at 48% [8] - Sales expenses increased, with sales expense ratios rising by 2.8 percentage points in 2024 and 4.3 percentage points in Q1 2025 [8] - Profit forecasts for 2025-2027 are as follows: - Net profit: 760 million yuan (2025), 901 million yuan (2026), 1.07 billion yuan (2027) - Growth rates: 10.0% (2025), 18.4% (2026), 19.2% (2027) [8] - The current price-to-earnings ratio (P/E) is projected to be 13X (2025), 11X (2026), and 9X (2027) [8] Market Position - The company is recognized as a leading pharmaceutical commercialization platform in China, demonstrating strong brand-building and multi-channel operational capabilities [8] - The company has successfully developed multiple products with revenues exceeding 100 million yuan and is accelerating its layout in innovative drugs and devices [8]

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.4536 | -0.6423 | 29.38 | -0.3905 | | 每股净资产（元） | 0.68 | 1.09 | -37.61 | 1.71 | | 每股公积金(元) | 0.8 | 0.82 | -2.44 | 0.81 | | 每股未分配利润(元) | -1.11 | -0.63 | -76.19 | -0.02 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 303.17 | 364.19 | -16.75 | 378.35 | | 净利润(亿元) | -11.93 | -16.9 | 29.41 | -10.27 | | 净资产收益率(%) | -50.71 | -43.94 | -15.41 | -19.35 | | 名称 | 持有数量(万股) | ...